Summary
Since hitting the market in 2015, drugs that target poly (ADP-ribose) polymerase (PARP) have transformed the clinical management of cancers harboring BRCA-mutations. As more PARP inhibitors have been commercialized, drug developers are turning their attention towards broadening drug labels and exploring combination strategies. This report covers the management of PARP inhibitors in the US, Europe, and Asia, focusing on efficacy and safety comparisons for approved products, current and future indications, and research and development strategies.
Scope
This report combines key opinion leader insight with in-house analyst expertise and research to provide an insight-rich look at PARP inhibitors in the US, Europe, and Asia. Components of the report include -
- Overview of PARP Inhibitors in Oncology: Background, mechanism of action, and clinical development of PARP inhibitors.
- Epidemiology Analysis: Which current and future disease spaces are relevant to PARP inhibitors.
- Marketed PARP Inhibitors: How the currently approved PARP inhibitors compare.
- Pipeline Assessment in the 8MM: What are the pipeline PARP inhibitor products in development in oncology.
- Key Players: What companies are developing PARP inhibitors in oncology.
- Research and Development Strategies: How are PARP inhibitor clinical trials being designed, and what combination strategies are being explored in the US, Europe, and Asia.
- Pricing, Reimbursement, and Regulatory Strategies: What current and future challenges face PARP inhibitors from a payer’s perspective.
Reasons to buy
- Develop business strategies by understanding the trends shaping and driving the PARP inhibitor market in the US, Europe, and Asia.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the portfolios of various competitors.
- Identify areas of unmet need within the PARP inhibitor market to help drive research and development towards future market opportunities.
- Gain insights to help plan and design your clinical trials.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
- Identify key pricing and reimbursement strategies.
Companies Mentioned
AbbVie
AstraZeneca
BeiGene
Clovis Oncology
Jiangsu Hengrui Medicine Co.
Merck
Nerviano Medical Sciences
Oncology Venture
Pfizer
Sanofi
SyntheX
Tesaro
'
Table of Contents
1. Preface
1.1 Table of Contents 2
1.2 Abbreviations 4
1.3 Related Reports 6
1.4 Upcoming Related Reports 7
2. Executive Summary 8
2.1 Key Findings 9
2.2 KOL Insight on PARP Inhibitor Competitive Landscape 10
3. Overview - PARP Inhibitors 11
3.1 The Role of PARP in DNA Repair 13
3.2 Mechanism of PARP Inhibitors in Cancer 14
3.3 History of PARP Inhibitor Clinical Development 15
3.4 PARP Inhibitors in Ovarian Cancer 17
3.5 PARP Inhibitors in Breast Cancer 20
3.6 PARP Inhibitors in Prostate Cancer 22
3.7 PARP Inhibitors in Pancreatic Cancer 23
3.8 PARP Inhibitors in Other Cancers 25
3.9 PARP Inhibitor Resistance and Long-Term Effects 26
4. Epidemiology Analysis 28
4.1 Epidemiology Analysis - Ovarian Cancer 30
4.2 Epidemiology Analysis - Breast Cancer 32
4.3 Epidemiology Analysis - Prostate Cancer 34
4.4 Epidemiology Analysis - Pancreatic Cancer 36
4.5 Epidemiology Analysis - Gastric Cancer 38
5. Marketed PARP Inhibitors 40
5.1 Timeline of PARP Inhibitors Clinical Development in the 8MM 42
5.2 Currently Marketed PARP Inhibitors in Oncology 43
5.3 KOL Input on Marketed PARP Inhibitors 49
6. Pipeline Assessment in the 8MM 52
6.1 Assessment of Ongoing Trials of Marketed PARP Inhibitors 54
6.2 Talazoparib (Pfizer) 56
6.3 Veliparib (AbbVie) 57
6.4 Pamiparib (BeiGene) 58
6.5 2X-121 (Oncology Venture) 59
6.6 Fluzoparib (Jiangsu Hengrui Medicine Co.) 60
6.7 PARP Trapping 62
6.8 KOL Input on Pipeline PARP Inhibitors 63
7. Key Players 65
7.1 Companies Developing PARP Inhibitors in Oncology 66
7.2 Analysis of the Company Portfolio Gap in PARP Inhibitors 67
7.3 KOL Input on Key Players 68
8. Clinical Trials Mapping and Design 69
8.1 Ongoing Clinical Trials of PARP Inhibitors Pipeline 71
8.2 KOL Input on Challenges in PARP Inhibitor Clinical Trial Design 80
9. Combination Strategies with PARP Inhibitors 83
9.1 Overview of Clinical Trials of PARP Inhibitors as Combination Therapy 85
9.2 Combination Strategy of PARP Inhibitors with Immunooncology 87
9.3 Combination Strategy of PARP Inhibitors with Angiogenesis Inhibitors 89
9.4 Combination Strategy of PARP Inhibitors with Chemotherapy 90
9.5 Combination Strategy of PARP Inhibitors with Other Drugs 91
10. Pricing, Reimbursement, and Regulatory Strategy 92
10.1 Current Strategies for Oncology Products 94
10.2 Differentiating Between Lynparza, Rubraca, and Zejula 95
10.3 Future PARP Inhibitors 97
10.4 PARP Inhibitor Challenges from US/UK Payers’ Perspective 98
11. Market Outlook and Future Use 100
11.1 Market Outlook 102
11.2 Anticipated Key Events in PARP Inhibitors 105
11.3 Future Uses of PARP Inhibitors in Oncology 106
12. Appendix 107
12.1 Sources 108
12.2 Methodology 109
12.3 Primary Research 110
12.4 About the Authors 112
12.5 About GlobalData 114
